ADVANCE: phase 2, randomised, double-blind, placebo-controlled study of adjunctive pimavanserin in patients with negative symptoms of schizophrenia

Authors
Category Primary study
JournalEUROPEAN NEUROPSYCHOPHARMACOLOGY
Year 2020
This article has no abstract
Epistemonikos ID: 8f8be1d9a84c79b5760c4cc52a43892f90e6f98d
First added on: Feb 12, 2025